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NHERF1/EBP50, an adaptor molecule that interacts with β-catenin, YAP, and PTEN, has been recently implicated in the
progression of various human malignancies, including colorectal cancer. We report here that NHERF1 acts as a tumor
suppressor in vivo for intestinal adenoma development. NHERF1 is highly expressed at the apical membrane of mucosa
intestinal epithelial cells (IECs) and serosa mesothelial cells. NHERF1-deficient mice show overall longer small intestine and
colon that most likely could be attributed to a combination of defects, including altered apical brush border of absorbtive IECs
and increased number of secretory IECs.NHERF1 deficiency in ApcMin/+ mice resulted in significantly shorter animal survival
due to markedly increased tumor burden. This resulted from a moderate increase of the overall tumor density, more
pronounced in females thanmales, and amassive increase in the number of large adenomas in both genders. The analysis of
possible pathways controlling tumor size showed upregulation of Wnt-β-catenin pathway, higher expression of unpho-
sphorylatedYAP,andprominentnuclearexpressionofcyclinD1 inNHERF1-deficient tumors.SimilarYAPchanges,with relative
decreaseofphosphorylatedYAPand increaseofnuclearYAPexpression,wereobservedasearly as theadenomastages in the
progression of human colorectal cancer. This study discusses a complex role of NHERF1 for intestinal morphology and
presents indisputable evidence for its in vivo tumor suppressor function upstreamofWnt-β-catenin andHippo-YAP pathways.
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Human colorectal cancer (CRC) is the third most common type of
cancer and the third cause of mortality due to cancer in the United
States [1]. It typically evolves from a benign polyp, or adenoma, to
malignant carcinoma that starts in the mucosa [carcinoma in situ;
American Joint Committee on Cancer (AJCC) stage 0] and spreads
through the other layers of the colon or rectum. In advanced stages,
malignant cells metastasize to the lymph nodes (AJCC stage III) or to
distant organs (AJCC stage IV). The ability of CRC cells to invade
and metastasize renders the tumors unresectable and resistant to
chemotherapy and diminishes abruptly the overall survival rate to
approximately 10% at 5 years for AJCC stage IV patients [2].
The understanding of the progression of CRC sets the foundation
for the development of therapeutic approaches. Approximately 85%
of sporadic CRCs have deregulation of the canonical Wnt-β-catenin
pathway, the same central pathway that is involved in intestinal
epithelial cell (IEC) renewal [3]. Wnt3, 6, and 9B expressed only in
the crypt epithelium bind to Frizzled transmembrane receptors and tolow-density lipoprotein receptor–related proteins-5/6 [4]. They
activate the pathway by disassembling the cytoplasmic destruction
complex formed by axin, Apc, GSK-3β, CK1α/ε, and β-catenin
[5,6]. In this complex, CK1 and GSK-3β phosphorylate β-catenin on
N-terminal residues and target it for proteasome degradation.
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thus stabilizes β-catenin. Subsequent translocation of β-catenin to the
nucleus and interaction with lymphoid enhancer factor/T-cell factor
DNA-binding proteins activate the transcription of Wnt target genes
[7], including cyclin D1 [8]. The almost always-present hit at the
level of the β-catenin destruction complex in CRC can explain the
growth of the tumors but cannot explain the phenotypic heteroge-
neity of CRC. Other contributions to enhance the activation of the
Wnt/β-catenin pathway have been documented, either from
components of the Wnt pathway itself or from parallel pathways
that connect to the Wnt pathway, such as the PI3-kinase-PTEN-Akt
pathway [9] or the Hippo-YAP/TAZ pathway [10,11].
We have shown that Na/H exchanger 3 (NHE3) regulatory factor 1
(NHERF1)/ ezrin-radixin-moesin (ERM) phosphoprotein 50 (EBP50),
an adaptor protein that interacts with β-catenin and PTEN [12,13], is
lost from the apical plasmamembrane (PM) of IECs in tubular adenoma
and CRC [14]. Interestingly, NHERF1 can be highly expressed in the
cytoplasm in a subset of CRCs [14] and in the nucleus in invasive CRC
fronts [15]. Cytoplasmic expression of NHERF1 increases cell
proliferation [14]. NHERF1 suppresses the Wnt-β-catenin pathway in
mouse embryonic fibroblasts [16], and its depletion from the apical PM
in polarized colonic two-dimensional (2D) and 3D cell models leads to
loss of cell polarity and gland morphology, disorganized solid growth,
epithelial to mesenchymal transition, and increased migration [14,17].
To establish whether NHERF1 also has a role in vivo as modulator of
CRC progression, we used the ApcMin/+ mice that constitute the most
used model for CRC development [18]. ApcMin/+ mice have a point
mutation in one APC allele and develop multiple intestinal neoplasia
(Min) by activation of theWnt-β-catenin pathway. AlthoughNHERF1
deficiency by itself led only to morphological defects, such as increased
intestinal length, NHERF1 deficiency in ApcMin/+ mice led to
significantly shorter animal survival due to increased tumor load. The
most striking difference was a marked increase in the numbers of large
adenomas. The tumors from ApcMin/+ mice had reduced NHERF1
expression and activation ofWnt-β-catenin pathway. The complete lack
of NHERF1 from ApcMin/+NHERF1−/− tumors induced even higher
Wnt-β-catenin pathway activation, higher expression of unphosphory-
lated YAP, and prominent nuclear cyclin D1 expression, attesting to the
important suppressor contribution of NHERF1 toWnt-β-catenin– and
YAP-driven tumorigenesis.
Materials and Methods
Mice and Intestine Analysis
The NHERF1-deficient mice [19] were inbred in C57BL/6J
background [20] and crossed to C57BL/6J ApcMin/+ mice (The
Jackson Laboratory, Bar Harbor, ME), inbred in the same C57BL/6J
background. The offspring were genotyped for the NHERF1 alleles as
described [19] and for the Apc alleles as indicated by the vendor. Mice
at various ages were euthanized by CO2 inhalation. The entire
intestinal tract was carefully dissected and measured. For tumor
analysis, consensus recommendations were followed [21]. Briefly, the
digestive tract was inflated and flushed with cold PBS; infused and
incubated in 10% formalin for 3 hours; separated in proximal one
third (duodenum and proximal jejunum), middle one third, distal
one third (distal ileum), and colon; cut open longitudinally; and Swiss
rolled on a paper tape with the serosa facing the tape and the proximal
end in the center of the Swiss roll. Following overnight fixation in
formalin and embedding, 5 levels (step sections) 0.5 mm apart wereexamined for each block. The numbers of neoplastic lesions,
microadenomas (diameter b 1 mm), and adenomas were counted for
each level, and the highest number per level was selected and scored as
tumor density for each intestinal segment. The size of the tumors was
measured with Leica Application Suite Version 4.3.0 software (Leica
Microsystem, Switzerland) on images acquiredwith 2×/0.06 or 4×/0.13
objective from an Olympus BX41 microscope (Olympus America Inc.,
Center Valley, PA) equipped with a Leica DFC450 camera. When the
adenoma was present on serial levels, the highest measurement was
scored. The analysis of the intestinal lesions was performed by a certified
anatomic pathologist, and the comprehensive analysis of the aged mice
was performed by an experienced veterinary pathologist. The latter
comprised soft tissues, such as lung, liver, kidney, spleen, stomach, and
Swiss-rolled intestines, along with the decalcified osseous tissues skull,
femur, and sternum.
Human Specimens
The frozen and formalin-fixed paraffin-embedded tissue resection
specimens from patients with CRC were obtained from the
Gastrointestinal Tumor Bank at MD Anderson Cancer Center
(Houston, TX) and were previously described [14]. Matched sets of
frozen specimens had the pathologist's annotations as normal, deep
tumor (carcinoma), and tumor edge (adenoma). Paraffin-embedded
resection specimens contain areas of adenoma, carcinoma, and
adjacent normal mucosa on the same slide.
Histology, Immunohistochemistry (IHC), and Immunofluorescence (IF)
Formalin-fixed, paraffin-embedded sections were stained with
hematoxylin and eosin (H&E) and Alcian blue by using standard
protocols. Mouse tissue sections were processed for IHC as described
[22] by using the Histomouse-Max kit (Zymed/Invitrogen, Carlsbad,
CA). Primary antibodies were applied overnight in a humidified
chamber at 4°C, with washing of unbound antibodies next day in PBS
for 5 minutes three times. The following primary antibodies and
corresponding dilutions were used: EBP50/NHERF1 1:3200
(PA1-090, ThermoFisher Scientific, Rockford, IL), β-catenin 1:300
(BD Biosciences, San Jose, CA), YAP 1:100 (4912) and P-YAP
1:2000 (13008) (Cell Signaling Technology, Danvers, MA), and
cyclin D1 1:1000 (Santa Cruz Biotechnology, Santa Cruz, CA).
Human tissue sections were processes for IHC as described [16]. For
IF, mouse tissues were processed as for IHC, except for blockage from
nonspecific binding for 30 minutes with 20% to 50% donkey serum
in PBS. The NHERF1 and E-cadherin (BD Biosciences) antibodies
were applied at 1:200. The secondary antibodies Alexa Fluor 488
donkey anti-rabbit IgG and Alexa Fluor 555 donkey anti-mouse IgG
(Molecular Probes/Invitrogen) were then applied at 1:500 each in
PBS for 45 minutes, followed by three PBS washes for 5 minutes.
Finally, the slides were incubated in ToPro-3 iodide (Molecular
Probes/Invitrogen) at 1:2000 in PBS for 20 minutes for nuclear
staining and then washed with PBS for 5 minutes twice. The
Slowfade Gold antifade reagent (Invitrogen) was used for the
mounting of the slides. Images were acquired with a Zeiss 510
confocal microscope (Carl Zeiss MicroImaging, Thronwood, NY)
using 40×/1.30 objective with oil immersion.Transmission Electron Microscopy
Approximately 1-mm3 colon mucosa samples were fixed with 3%
glutaraldehyde and 2% paraformaldehyde in 0.1 M sodium
cacodylate buffer (pH 7.3), postfixed with 1% osmium tetroxide,
514 NHERF1 Deficiency Promotes Intestinal Neoplasia In Vivo Georgescu et al. Neoplasia Vol. 18, No. 8, 2016and stained en bloc with 1% uranyl acetate. Samples were dehydrated
in increasing concentrations of ethanol, infiltrated, embedded in
Epon medium, and polymerized at 70°C for 2 days. Ultrathin
sections were stained with uranyl acetate and lead citrate and
examined in a JEM 1010 transmission electron microscope (JEOL
USA Inc., Peabody, MA). Digital images were obtained by using
AMT Image System (Advanced Microscopy Techniques, Danvers,
MA).
BrdU Labeling
NHERF1 wild-type andmutantmice were injected intraperitoneally
with 0.1 ml/10 g body weight of BrdU (Invitrogen), and sacrificed
2 hours later. Organs were harvested, fixed in 10% formalin overnight,
and processed for IHC with the Animal Research Kit (Dako,
Carpinteria, CA).
Plasmids, Transfections, and Protein Analysis
Human cDNAs for full-length NHERF1 and for the PDZ1 and
PDZ2 domains were previously described [13]. They were inserted in
frame with an Myc tag in the pcDNA3 vector. FLAG-tagged YAP
wild type and YAP-S127A mutant in pCMV vector were kind gifts of
Dr. K. Bhat, MD Anderson Cancer Center. The control short hairpin
RNA (shRNA) and NHERF1 shRNA-1 and 4 in pSIREN-RetroQ
vector and the protocol for retroviral infection of human Caco-2 CRC
cells were previously described [14]. The protocols for 293T human
embryonic kidney cells transfection, cell lysis, immunoprecipitation,
and Western blot were previously described [23]. The cell lysis and
Western blot analysis of human frozen samples were performed as
described [14]. Subcellular fractionation in nuclear, cytoplasmic, and
membrane compartments was described [16]. Antibodies for Western
blot were obtained from the following: Myc: Invitrogen; FLAG (M2):
Sigma-Aldrich, St. Louis, MO; YAP (4912) and P-YAP (4911): Cell
Signaling Technology; PTEN (A2B1), PARP (H-250), and GAPDH
(0411): Santa Cruz Biotechnology; E-cadherin: BD Biosciences; and
villin: Chemicon/Millipore, Temecula, CA.
Statistics
All numerical data were examined for normality of distribution and
expressed as means ± standard error of the mean (SEM) unless
mentioned otherwise. Unpaired two-tailed t test with or without
Welch correction for variances significantly different was used to
analyze the differences between groups. Kaplan-Meier survival
analysis using Gehan-Breslow-Wilcoxon test was plotted with the
GraphPad Prism program (GraphPad Software, La Jolla, CA). The
densitometric analysis was performed with ImageJ program (National
Institutes of Health, Bethesda, MD). Data are representative of at
least two or three independent experiments with similar results.
Statistical significance was considered for P b .05.
Results
Altered Intestinal Length and Cell Composition in NHERF1
Deficient Mice
NHERF1 deficiency leads to morphological alterations of some
specialized epithelia or epithelial-like linings in the body, including
mammary gland, cohlea, and ependyma, resulting in dysfunction
[20,24,25]. We have previously shown disruption of the brush border
membrane and increase of goblet cells in the small intestine of
NHERF1-deficient mice [19]. To better assess the intestinal defects,
we analyzed the intestine in cohorts of approximately 19.5-month-oldNHERF1+/+ and NHERF1−/− littermates. Inspection showed
significantly longer small intestine and colon in both male and
female NHERF1−/− mice (Figure 1A). Complete histopathologic
assessment of these mice showed a series of lesions associated with age
(Supplementary Table 1). Of these, malignancies such as lymphoma
and histiocytic sarcoma appeared equally distributed in NHERF1+/+
and NHERF1−/− mice. Lymphoid hyperplasia was present in various
locations in the majority of mice but appeared more extensive in
NHERF1−/− mice. Nephropathies, such as glomerulonephritis and
lymphocytic tubulointerstitial nephritis, and lymphocytic sialo- and
dacryoadenitis were lesions much more commonly found inNHERF1−/−
mice (Supplementary Table 1).
To examine whether the intestinal defects are developmental or
adaptative, we performed a prospective analysis in cohorts of
NHERF1+/+ and NHERF1−/− inbred mice sacrificed at 6, 12 and
24 weeks. Of note is that a large proportion ofNHERF1−/− mice have
small weight at 3 weeks of age because of maternal lactation deficit
[20]; therefore, the analysis of the intestine started at 6 weeks of age,
when NHERF1+/+ and NHERF1−/− mice showed comparable
weights. The small intestine and colon were separately measured for
males and females, and the length was expressed as length index, the
ratio of absolute length to the body mass (Figure 1B). In comparison
to control NHERF1+/+ mice, the small intestine length index was
significantly higher for NHERF1−/− male mice for all age groups and
for NHERF1−/− female mice for two of three age groups (Figure 1B,
upper graphs). For 12-week-old females, a trend was present, but the
difference was not statistically significant. Similar results were found
for the colon length index (Figure 1B, middle graphs). The body mass
of NHERF1+/+ and NHERF1−/− mice was equivalent at 6 weeks
of age for both genders and at 12 and 24 weeks for female mice
(Figure 1B, lower graphs). NHERF1+/+ males showed a steeper
growth curve compared to NHERF1−/− counterparts at 12 and 24
weeks of age, with statistically significant higher body masses at these
time points. However, old males had equivalent body masses, whereas
the weight distribution for old females, especially wild type, was
scattered (Figure 1A).
To find out why NHERF1-deficient mice have longer intestines
than their wild-type counterparts, we examined the expression of
NHERF1 in the intestine. While it is well known that NHERF1 is
expressed in IECs (Figure 2A, yellow arrowhead) [26,27], it also has
high apical PM expression in the mesothelial cells of the serosa as well
(Figure 2A, arrow) [26]. IECs result from the proliferation of
intestinal stem cells through transit-amplifying/progenitor cells in the
crypts followed by terminal differentiation into four mature
populations: absorbtive cells, goblet cells, Paneth cells, and
neuroendocrine cells [7]. The proliferation of progenitor cells was
measured by BrdU incorporation and was equivalent in the crypts of
NHERF1+/+ and NHERF1−/− mice (Figure 2B). As control, splenic
cells showed higher proliferation in NHERF1−/− mice. However, the
localization of the NHERF1−/− BrdU-labeled progenitors appeared
shifted to upper positions in the crypts. By matching the number of
BrdU-positive cells with the cell position from the crypt bottom, we
confirmed this observation (Figure 2B). This implied that there is a cell
population that displaces upward the progenitor cells in the crypts. The
examination ofH&E small intestine sections revealed increased numbers
of Paneth cells in the NHERF1−/− crypts (Figure 2C, arrows). Staining
for lysozyme that specifically identifies secretory Paneth cells in crypts
and with Alcian blue that highlights goblet cells showed increased
numbers of both types of these secretory IECs in NHERF1−/− intestine
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Figure 1. Increased intestinal length inNHERF1−/−mice. (A and B) The length of the small intestine (SI) and colon and the bodymass (BM)
were recorded at 85 weeks (A) and 6, 12, and 24 weeks of age (B) in cohorts of male and female mice. The length index was calculated as
the ratio of intestine length to body mass. The SI and colon length, length index, and body mass are expressed as mean ± SEM. The
groups were compared by t test, and the P values for significant differences are indicated in red. Note increased intestine length in
NHERF1−/− mice as compared to control NHERF1+/+ mice.
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progenitor cells into the various populations of IECs.We have previously
shown ultrastructural defects of the brush border membrane of
absorbtive IECs in the ileum [19]. Ultrastructural analysis of the colon
brush border revealed shorter microvilli of theNHERF1−/− colonocytes,
with a length of approximately 67% the length of wild-type microvilli
(Figure 2D), confirming previous independent findings in colon [28].
These results suggest that the alterations of IECs might be at least in part
responsible for the increased intestine length of NHERF1−/− mice.
Decreased Survival and Increased Tumor Load in NHERF1
Deficient APC Mutant Mice
Pathways involved in tissue morphogenesis often play roles in
tumorigenesis as well. One such pathway is the Wnt-APC-β-catenin,
which is the key pathway involved in both morphogenesis and
tumorigenesis in the intestine [29]. We have previously demonstrated
that NHERF1 downregulation induces tumorigenic effects in human
intestinal cells in 2D and 3D tissue models [14,17]. Because we found
that NHERF1 is involved in intestinal morphogenesis, we explored
the possibility that it may act as a tumor suppressor in vivo as well.
NHERF1−/− mice were crossed to ApcMin/+ mice, and the offspringcarrying the Min allele were selected for survival analysis (Figure 3A).
Double-mutant ApcMin/+NHERF1−/− mice had a median survival
of 19 weeks, markedly shorter than the ApcMin/+NHERF1+/+
counterparts. Interestingly, no significant difference was observed
between the double-heterozygous ApcMin/+NHERF1+/− mice and the
ApcMin/+NHERF1+/+ mice, and their median survivals were 28 and
29 weeks, respectively. This suggests that one wild-type NHERF1
allele is sufficient to provide adequate functional levels of NHERF1.
To study tumor development, new cohorts of ApcMin/+NHERF1+/+
and ApcMin/+NHERF1−/− mice were sacrificed at 16 weeks (Figure 3B).
This time point that closely precedes the median survival of
double-mutant ApcMin/+NHERF1−/− mice was chosen based also on a
previous study showing no increase in the number of tumors detected in
ApcMin/+mice after 80 days of age [30]. At 16 weeks,ApcMin/+NHERF1−/−
mice had lower bodymass thanApcMin/+NHERF1+/+mice (P = .05), most
likely because of more advanced disease (Figure 3B). An enhanced
production of IL-6 has been associated to cachexia in ApcMin/+ mice [31].
All ApcMin/+ mice showed signs of anemia, such as pale limbs and
compensatorily enlarged spleens with increased extramedullary hemato-
poiesis (Figure S1). In both humans with CRC and in ApcMin/+ mice,
chronic bleeding due to a compromised intestinal epithelial lining leads to
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small intestine and colon were dissected and prepared as Swiss roll for
histological examination (Figure S2). Neoplastic lesions, including
adenomas (diameter N 1 mm) and microadenomas, were counted and
the highest tumor density scored (Figures S3-S4). The double-mutant
ApcMin/+NHERF1−/− mice had a significantly higher tumor density in
the small intestine than ApcMin/+NHERF1+/+ mice (Figures 3, B and C
and S5). We noticed a tendency of developing more tumors in ApcMin/+
females than in males, which was even more pronounced in the
double-mutant mice, with statistically significant differences of 34% and
73%, respectively (Figures 3B and S5). The regional tumor distributionwas
similar for both genotypes, with an increasing gradient along its length
resulting in consistently higher polyp numbers in the distal segment than inthe rest of the intestine (Figure 3D). This distribution in C57BL/6J
ApcMin/+ mice is consistent with previous studies [33,34]. The
tumorigenesis in the colon was much less developed than in the intestine,
with only few or no polyps present, and a significant difference between
ApcMin/+NHERF1−/− and ApcMin/+NHERF1+/+ mice was noted only for
females (Figure 3B).
All adenomas (diameter N 1 mm) were measured on each section
level, and the highest measurement for a single tumor was scored
(Figure S4). ApcMin/+NHERF1−/− mice had double the number of
adenomas of ApcMin/+NHERF1+/+ mice (Figure 3E and Table S2).
The partition of adenomas on gender showed only slight preponder-
ance in double-mutant females (Figure S5). Adenomas were
segregated also in four consecutive size categories (Figure 3F). A
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in the whole intestine in all mice and per gender (E), and adenoma distribution of sizes in the whole intestine (F). Adenomas were defined as
tumors with diameter larger than 1 mm. The regional distribution of very large adenomas (N2.5 mm) is also shown in (F).
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double-mutant ApcMin/+NHERF1−/− mice, irrespective of gender.
Strikingly, the largest tumors were on average seven times more
numerous in ApcMin/+NHERF1−/− mice than in ApcMin/+NHERF1+/+
mice (Figure 3F, lower graph and Table S2). Interestingly, thedistribution of these large adenomas (N2.5 mm) was in the proximal
and middle segments of the small intestine and in the colon, and
attained very large sizes in double-mutant ApcMin/+NHERF1−/− mice,
especially in the colon (Figure 3F, right graph). In ApcMin/+NHERF1+/+
mice, large adenomas were seen only in the proximal segment of the
518 NHERF1 Deficiency Promotes Intestinal Neoplasia In Vivo Georgescu et al. Neoplasia Vol. 18, No. 8, 2016small intestine. Concurrently, the regional distribution of adenomas in
thesemice was blunted, indicating thatmost of the tumors were small at
16 weeks of age (Figure 3D). In contrast, the regional distribution of
adenomas in ApcMin/+NHERF1−/− mice respected the incremental
gradient along the intestine, suggesting an increased tumor growth rate
that parallels the rate of tumor initiation in these mice (Figure 3D). The
histology of the tumors was that of tubular adenoma with or without
high-grade dysplasia (Figure S6).Occasional gland herniationwas noted
at the base of the polyp but without frank invasion. Metastatic workup
of liver and lung in four ApcMin/+NHERF1−/− animals examined at the
time of death did not find evidence of metastatic disease.
Overall, this analysis showed that the tumor load, including both
the tumor density and tumor size, was significantly higher for both
genders of the ApcMin/+NHERF1−/− mice (Supplementary Table 2
and Figure S5), explaining the shorter survival of these animals.
Increased β-Catenin, YAP and Cyclin D1 Nuclear
Localization in Tumors from NHERF1 Deficient Mice
The finding of larger adenomas in ApcMin/+NHERF1−/− than in
ApcMin/+NHERF1+/+ mice at a given time point suggested a higher
growth rate for ApcMin/+NHERF1−/− tumors. To investigate the
tumor suppressor function of NHERF1 on adenoma growth, we
first examined the expression levels of NHERF1 in tumors from
ApcMin/+NHERF1+/+ mice. Compared to normal surrounding
mucosa, both microadenomas and macroadenomas had decreased
NHERF1 expression levels by IF and IHC (Figures 4A and S7). This
result suggests a growth suppressor role of NHERF1 and is similar to
results from human CRC, where NHERF1 loss from the apical PM
occurs from early adenoma stage [14].
We and others have shown that NHERF1 controls tumor growth
through interactions with tumor suppressor or oncogenic proteins
[35] (Figure 4B). More specifically, NHERF1 suppresses the PI3
kinase-Akt pathway by interacting with PTEN tumor suppressor
[13], and the Wnt-β-catenin pathway by interacting with β-catenin
and Frizzled family members [12,16,36]. Recently, links between the
Wnt-β-catenin pathway and YAP, the downstream effector of the
Hippo pathway, have been revealed [11]. NHERF1 has been
previously shown to interact with YAP [37], but the implications of
this interaction for tumor growth have not been studied. We
confirmed that NHERF1 and YAP co-immunoprecipitate and that
the interaction is mediated through the PDZ2 domain of NHERF1
(Figure 4C), as previously reported [37]. We also found that
NHERF1 interacts robustly with the YAP-S127A phosphorylation-
deficient mutant (Figure 4C). Phosphorylation of YAP on S127 by
LATS1/2, the most downstream kinases of the Hippo pathway,
retains YAP in the cytoplasm, limiting its translocation to the nucleus
and the transcriptional activation of genes involved in cell
proliferation [11]. To investigate the role of NHERF1 in YAP
signaling, we depleted NHERF1 in polarized Caco-2 CRC cells and
performed subcellular fractionation (Figure 4D). We have previously
shown that NHERF1 depletion in these cells leads to epithelial to
mesenchymal transition with loss of apical cell polarity [14]. We
confirmed the loss of apical polarity in NHERF1-depleted cells by the
downregulation of villin, a protein involved in the structural assembly
of microvilli (Figure 4D). In NHERF1-depleted cells, phosphorylated
YAP was decreased in the cytoplasmic compartment, whereas
unphosphorylated YAP was increased in the nuclear compartment
(Figure 4D), consistent with the translocation of unphosphorylated
YAP to the nucleus in the absence of NHERF1.In human CRC cells, depletion of NHERF1 from the apical PM
also results in β-catenin translocation to the nucleus, presumably due
to polarity loss and epithelial to mesenchymal transition [14,17]. As
previously noted in ApcMin/+ mice, the expression of β-catenin
increased in tumors compared to adjacent normal mucosa [38], and
we also observed this pattern regardless of the NHERF1 genotype.
However, in ApcMin/+NHERF1−/− mice, tumors showed higher
expression of β-catenin, including nuclear β-catenin (Figure 4E).
In normal intestine, both phosphorylated YAP and total YAP were
expressed in the crypt epithelium and not in the villi (Figure S8A). The
aberrant crypt foci exhibited similar expression levels as the surrounding
crypts (Figure S8A). Whereas YAP had nuclear expression in some
neoplastic cells of tumors from ApcMin/+NHERF1−/− mice (Figure 4E),
phosphorylated YAP was mostly restricted to the cytoplasmic cell
compartment of these tumors where it appeared decreased (Figure S8B).
The findings from ApcMin/+NHERF1−/− tumors were similar to
those from Caco-2 NHERF1-depleted cells (Figure 4, D and E),
suggesting that NHERF1 controls the nuclear translocation of YAP
in vivo and in vitro.
Strikingly, cyclin D1, a downstream effector of the Wnt/β-catenin
pathway in CRC [8] but also of the Hippo-YAP pathway [39],
had prominent nuclear expression in the neoplastic glands from
ApcMin/+NHERF1−/− tumors and not in the normal mucosa (Figure 4E).
The nuclear expression of cyclinD1 fromApcMin/+NHERF1−/− tumors was
much higher and diffuse than that seen in ApcMin/+NHERF1+/+ tumors
(Figure 4E), explaining the faster growth rate of the ApcMin/+NHERF1−/−
tumors. Although NHERF1 is a positive regulator of PTEN tumor
suppressor [13] and PTEN suppresses cyclin D1 levels [40], we could
not find elevated phosphorylated Akt by IHC in the tumors examined
(not shown).
Analysis of YAP and Phosphorylated YAP Expression
in Matched Normal-Adenoma-Carcinoma
Specimens of Human CRC
We have previously shown in matched normal-adenoma-carcinoma
specimens thatNHERF1membrane expression is lost early in adenoma
and that loss or cytoplasmic overexpression is present in carcinoma [14].
Examination of the expression levels of phosphorylated YAP in the same
series of frozen specimens by Western blot showed a sharp drop from
early initial adenoma stages (Figure 5A). Total YAP expression levels
decreased much less and more gradually in the sequence
normal-adenoma-carcinoma, resulting in a relative decrease of
phosphorylated YAP as compared to total YAP (Figure 5A, upper
graph). IHC of resection specimens with normal, adenoma, and
carcinoma histology on the same slide showed amarked increase of YAP
nuclear staining from normal to adenoma and carcinoma stages, with
moderate and prominent nuclear staining in adenoma and carcinoma,
respectively (Figure 5B, lower panels). This suggested activation of the
transcriptional growth program regulated by YAP. IHC with P-YAP
antibody showed the presence of phosphorylated YAP in the cytoplasm
of cells in normal, adenoma, and carcinoma tissues with similar levels in
adenoma and carcinoma (Figure 5B, middle panels). Occasional
moderate nuclear staining was noted in adenoma and carcinoma. In
some cases, the levels of phosphorylated YAP appeared lower in normal
epithelial cells, as in the case depicted in Figure 5B. Interestingly, the
smooth muscle of muscularis mucosae and of the small arteries in the
submucosa expressed phosphorylated YAP in the cytoplasm (Figure 5B,
arrows). As these components are usually present in a normal mucosal
biopsy, the high levels of phosphorylated YAP noted in the normal
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smooth muscle cells. However, normalization of these levels to
total YAP, also present in the same smooth muscle cell compartments
(Figure 5B, arrows), most likely reflected the fraction of YAP that
is phosphorylated overall. Altogether, the relative decrease of
phosphorylated YAP and the increase of YAP nuclear expression in
human CRC samples were in concordance with the observations from
ApcMin/+NHERF1−/− mice.N A C 
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and colon, including attenuated brush border of absorptive IECs,
increased numbers of secretory IECs, and significantly increased
length. The latter reaches 24% increase for aged females (at 84% of
wild-type body mass) and 15% increase for aged males (at 103% of
wild-type body mass) in the small intestine, and 11% increase for
both genders in the colon. Smaller but significant differences are also
detected in very young mice, arguing for a combination of
developmental and adaptive determining factors. NHERF1 interacts
with and regulates the activity of ion exchangers and channels, such as
NHE3 and CFTR [28,41–43] that are expressed in the intestinal
brush border. NHE3-deficient mice have absorptive defects and
compensatory enlarged small intestine and colon, although by
distension rather than by increased segmental length [44]. CFTR
mutant mice have increased numbers of goblet cells in the ileum
similar to NHERF1-deficient mice, and mildly increased small
intestine length (by 10%) [45,46]. To our knowledge, the increase in
intestinal length in the NHERF1-deficient mice is the highest
reported, being most likely due to contributions from an altered
mucosa and possibly serosa.
As this is the first demonstration of the tumor suppressor role of
NHERF1 in vivo, we undertook a thorough analysis of the
tumorigenesis in the intestine. NHERF1 deficiency in the context
of the APC mutation in ApcMin/+ mice leads to drastic shortening of
the survival of double-mutant mice due to significantly increased
tumor load. The complete absence of NHERF1 expression is required
for tumorigenesis, as heterozygous NHERF1 mice do not show a
different phenotype from NHERF1 wild-type mice. One intriguing
observation in our cohorts was the difference in tumorigenesis
between ApcMin/+ male and female mice. The tumor density was
increased in female mice of both genotypes, whereas adenomas
developed at a similar rate in both genders in ApcMin/+ mice and yet
again with female predominance in Apc Min/+NHERF1 −/−
double-mutant mice. One correlation is the regulation of NHERF1
expression by estrogen receptor [47] and its variation in rodent
intestine during estral cycle [48]. Although this could explain the
limited growth of adenomas in ApcMin/+ females by a suppressor
effect of NHERF1, more studies are necessary to address the
increased tumor incidence in ApcMin/+ females. Interestingly,
NHERF2, the homolog of NHERF1, appears to have an opposite
role in tumorigenesis, as double-mutant ApcMin/+NHERF2−/− mice
develop smaller albeit not fewer tumors than ApcMin/+ controls [49].
Comparison to other mutant mice on ApcMin/+ background showed
that the tumorigenesis in NHERF1-deficient mice best resembles the
one developing in the cyclin-dependent-kinase (cdk) inhibitor Cdkn1b
(p27)-deficient mice [34,50], except that the latter shows gene dosage
dependence. Similarly to p27, NHERF1 deficiency results in a
moderately increased tumor incidence but a marked increase in the
number of large adenomas. Also like p27, NHERF1 expression is
reduced in tumors from single-mutant ApcMin/+ mice, suggesting
causal relationship to tumor growth. Although cyclin D1 expression
has not been investigated in Cdkn1b-deficient mice, the mitotic index
was increased in tumors from these mice, consistent with increased
tumor cell proliferation [34]. In NHERF1-deficient mice, the
expression and nuclear localization of cyclin D1 were massively
increased in tumors, suggesting accelerated cell cycle progression and
growth. Indeed, the role of cyclin D1 for tumor growth but not tumor
initiation following APC loss in the intestine has been established, as
cyclin D1–deficient mice develop the same number of tumors asmatched controls but fail to develop adenomas, defined as lesions with
diameter N 1 mm, as in our study [51].
Analysis of possible pathways upstream of cyclin D1 upregulation
in ApcMin/+NHERF1−/− tumors showed elevated levels of cytoplasmic
and nuclear β-catenin and elevated levels of nuclear YAP. The
involvement of these pathways downstream of NHERF1 may explain
not only the intestinal oncogenesis from NHERF1-deficient mice but
perhaps some of the morphological defects, such as increased
numbers of secretory cells. YAP has been recently shown to promote
the differentiation of intestinal stem cells into goblet cells [52], and
Wnt overactivation by APC loss leads to overproduction of Paneth
cells [53]. Interestingly, CFTR mutant mice that share some similar
morphological intestinal defects as NHERF1-deficient mice have also
increased intestinal tumorigenesis on an ApcMin/+ background that
may be due to increased Wnt -β-catenin pathway [54].
Mechanistically, NHERF1 interacts through its PDZ2 domain with
both β-catenin and YAP [12,37], and a direct interaction between
NHERF1 and some members of the Frizzled family has also been
documented [36] (Figure 4B). We have previously shown that
NHERF1 contributes to the stabilization of E-cadherin–β-catenin
complexes at the PM in mouse embryonic fibroblasts and also human
CRC cells [14,16]. NHERF1 deficiency leads to E-cadherin and
β-catenin drop from the PM, increase in cytoplasmic and nuclear
β-catenin, and β-catenin promoter transactivation [16]. The interac-
tion between NHERF1 and YAP has been involved in the
compartmentalization of YAP at the apical PM in polarized airway
epithelial cells [37]. We have shown here that NHERF1 deficiency,
either by shRNA knockdown in CRC cells or by gene knockout in
mice, leads to accumulation of unphosphorylated active YAP that most
likely contributes to tumorigenesis either by inducing target genes of
the transcriptional YAP/TAZ-TEAD complex or by entering in a
transcriptional complex containing β-catenin [11] (Figure 4B). The
nuclear expression of unphosphorylated YAP was also confirmed in
human CRC samples. Although YAP has been found at the apical PM
in airway cells [37], it is mainly distributed in the cytoplasm of normal
crypt cells in the intestine. Whether the mechanism of YAP nuclear
translocation involves direct interaction between the cytoplasmic
fractions of NHERF1 and YAP with sequestration of the unpho-
sphorylated YAP fraction in the cytoplasm or a more indirect signaling
involving YAP dephosphorylation [55] is unknown at the present time.
In conclusion, we show here that NHERF1 loss from the PM is
oncogenic in vivo through its influence on Wnt-APC-β-catenin and
Hippo-YAP pathways. Further in vivo studies are required to extend this
role to other malignancies dependent of the Wnt-β-catenin pathway and
to dissect the functions of NHERF1 in other subcellular locations. The
understanding of the function of NHERF1 will trigger the refinement of
the ongoing therapeutic efforts for modulating its activity [56,57].
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